High demand means high wages for engineers in medical manufacturing

The most recent numbers from the Bureau of Labor Statistics suggest that engineers working in the manufacture of medical equipment and supplies are enjoying something of a golden age.

The lowest average salary earned by any engineering position in the category, $77,020 for mechanical engineers, is nearly 85 percent higher than the national average wage index, $41,674. (The latter is tabulated by the Social Security Administration based primarily on wages subject to federal income tax.)

At the top of the heap, materials engineers command an annual mean wage of $95,180. The bureau includes under this position metallurgists and metallurgical engineers, ceramic engineers, welding engineers and other engineers who “evaluate materials and develop machinery and processes to manufacture materials for use in products that must meet specialized design and performance specifications.”

Rounding out the top five for average annual earnings in the sector are chemical engineers ($89,670), health and safety engineers ($86,350), biomedical engineers ($86,280) and electronics engineers ($85,710).

On the webpage that presented these figures, the bureau notes that it calculates its industry-specific occupational employment and wage estimates with data collected from employers of all sizes around the U.S.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.